News

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed.

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

According to the company, Eyconis Inc. is developed with a $150 million commitment from external investors.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

The study also pointed out the insight into the genes and biologic pathways that determine retinal health, which could be leveraged to develop future therapies.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

The afternoon sessions promise to be engaging and informative in this virtual conference.

John T. Thompson, MD, FASRS, shares pearls for navigating the diverse landscape of career paths in ophthalmology as the Distinguished Guest Speaker at the 24th Annual Retina Fellows Forum.

According to researchers at Johns Hopkins Children’s Center, AI-driven cameras take images of the back of the eye and require no eye drops can be used to close care gaps.

This meeting, scheduled for Saturday, February 3, 2024, is a 1-day virtual event sponsored by the Bascom Palmer Eye Institute, Miami, University of Miami Health System.

Leanne Clevenger, MD, described a case that highlights varying approaches and protocols for addressing a complex case of retinal detachment repair in a patient with trauma to the globe.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

David Hutton of Ophthalmology Times talks with Sunir Garg, MD about his surgical video panel at this year's Retina Fellows Forum.

The American subsidiary of the German ophthalmic diagnostic device designer announced in a news release that its OCULUS Easyfield VR™ is now available in the US ophthalmic market

A recent study found that despite worldwide reports of ocular inflammatory events being reported after patients received COVID-19 vaccinations, a low amount has been reported in the UK.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

The app is a tool aimed at allowing patients to measure their visual acuity at home by themselves.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Consensus, awareness, and a CVI registry: top priorities of the trans-NIH event

The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.

Kamuvudines are a new class of inflammasome inhibitor drugs as therapies for prevalent, degenerative diseases. The trial is evaluating SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.